Evidence map›Paper›PMID 39959134›Full record

ArticleRheumatology advances in practice2025

Anti-citrullinated protein antibody detection by hemagglutination.

Ilmar Kruis, Jyoti Kumari, Annemarie van der Heijden, Amrah Weijn, Wilma Vree Egberts, Iris Rose Peeters, Noortje van Herwaarden, Martin Salden, Ger J M Pruijn

Abstract read
In one paragraph

Article in Rheumatology advances in practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ilmar KruisDepartment of Biomolecular Chemistry, Institute for Molecules and Materials, Radboud University, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0003-4118-4670
Jyoti KumariDepartment of Biomolecular Chemistry, Institute for Molecules and Materials, Radboud University, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0003-4752-4533
Annemarie van der HeijdenDepartment of Biomolecular Chemistry, Institute for Molecules and Materials, Radboud University, Nijmegen, The Netherlands.
Amrah WeijnDepartment of Biomolecular Chemistry, Institute for Molecules and Materials, Radboud University, Nijmegen, The Netherlands.
Wilma Vree EgbertsDepartment of Biomolecular Chemistry, Institute for Molecules and Materials, Radboud University, Nijmegen, The Netherlands.
Iris Rose PeetersDepartment of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0002-7991-6112
Noortje van HerwaardenDepartment of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0002-9527-851X
Martin SaldenNovio Catalpa BV, Nijmegen, The Netherlands.
Ger J M PruijnDepartment of Biomolecular Chemistry, Institute for Molecules and Materials, Radboud University, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0001-7208-6200

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: ACPAs play an important role in the classification of RA and can be detected by serological tests. Several ACPA detection assays are available for clinical use, which are all based on ELISA(-like) tests with citrullinated peptides (CCP2) or alternative citrullinated proteins/peptides. We aimed to facilitate ACPA detection in low-volume laboratories and resource-poor environments by developing a rapid and easy-to-perform test. Methods: We designed and generated an agglutination mediator by protein engineering. A single-chain antibody fragment that binds to glycophorin A, one of the major surface proteins of erythrocytes, was conjugated to a CCP2-like peptide. This agglutination mediator was used to assess ACPA in RA and PsA patients and in healthy individuals. Results: The agglutination mediator bound to erythrocytes was reactive with ACPA and induced haemagglutination in an ACPA-dependent fashion, which can be detected by the naked eye. The applicability was assessed by the analysis of fresh blood samples from 204 RA patients, 77 PsA patients and 100 healthy individuals. Agglutination was observed in up to 61% of the RA samples, which correlated well with the results obtained with a standardized anti-CCP2 ELISA (63-67%). Depending on the minimal agglutination score, agglutination was observed in only 3-21% of the PsA samples and in 1% of the healthy controls. Conclusion: We conclude that the agglutination mediator allows rapid and efficient detection of ACPA by haemagglutination in human blood samples and offers a low-threshold method for ACPA detection.

Indexed as

ACPAagglutinationanti-CCPautoantibodyrheumatoid arthritis

Identifiers

PMID39959134
PMCPMC11829806

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.